tiprankstipranks
ArriVent Biopharma price target raised to $39 from $35 at Oppenheimer
PremiumThe FlyArriVent Biopharma price target raised to $39 from $35 at Oppenheimer
5M ago
ArriVent Biopharma price target raised to $36 from $30 at H.C. Wainwright
Premium
The Fly
ArriVent Biopharma price target raised to $36 from $30 at H.C. Wainwright
5M ago
ArriVent announces PoC global Phase 1b interim data for firmonertinib
Premium
The Fly
ArriVent announces PoC global Phase 1b interim data for firmonertinib
5M ago
PremiumCompany AnnouncementsArriVent BioPharma’s Strategic Alliance for Cancer Drug Development
8M ago
ArriVent Biopharma announces multi-target ADC collaboration with Alphamab
Premium
The Fly
ArriVent Biopharma announces multi-target ADC collaboration with Alphamab
8M ago
Premium
Company Announcements
ArriVent BioPharma Welcomes Dr. Hohneker to Board
9M ago
Apple, Tesla downgraded: Wall Street’s top analyst calls
PremiumThe FlyApple, Tesla downgraded: Wall Street’s top analyst calls
12M ago
ArriVent Biopharma initiated with a Buy at Jefferies
Premium
The Fly
ArriVent Biopharma initiated with a Buy at Jefferies
12M ago
ArriVent Biopharma initiated with a Buy at Citi
Premium
The Fly
ArriVent Biopharma initiated with a Buy at Citi
12M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100